Dr. Thomas Neumann is a former physician and Research Assistant Professor at the University of Washington. He has nearly ten years of experience in the biotechnology industry, with special interests in developing platforms for cancer diagnostic and microfluidic systems for reproducing tissue and organ microenvironments in vitro. He is the key inventor of Nortis’ proprietary tissue-engineering technology. Dr. Neumann received his M.D. summa cum la

Dr. Alan Nelson is a visionary entrepreneur who has launched several successful companies in the biotech sector. His first company, NeoPath, developed the first automated screening platform for cervical cancer. Dr. Nelson’s academic career path includes professor appointments at MIT, Harvard, and the University of Washington. He is the former executive director of the Biodesign Institute at ASU, where he now leads the Predictive Health Analytics

Dr. Tourovskaia leads the cell biology research at Nortis. In her previous positions at the University of Washington she gained great expertise in the design and fabrication of microfluidic systems for the study of cellular functions in vitro. Her expertise lies in the investigation of biological phenomena at the micron and submicron scales, as well as in miniaturization cell culture technologies. Dr. Tourovskaia received her Ph.D. in Bioengineer

Mark Fauver is Nortis’ lead engineer and is responsible for the design and manufacture of Nortis’ microfluidic devices as well as the supporting bioreactor hardware. Mark Fauver has profound skill sets in microfabrication, imaging, automation, and software development. In his previous positions, he has designed and built several successful instruments, among them an ultra-thin endoscope and a 3D cell-imaging platform. Mr. Fauver holds a Master’s